BACKNoninvasive markers in maternal plasma for the prediction of pregnancy-associated complications
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 1 August 2025]
We are inviting expressions of interest (EoI) for commercializing “Noninvasive markers in maternal plasma for the prediction of pregnancy-associated complications” technology. The innovation is developed by Professor POON Liona Chiu-Yee, Professor of Department of Obstetrics and Gynaecology of The Chinese University of Hong Kong (CUHK Reference: 23/MED/1253).
The Technology
Circulating markers in peripheral blood represents a source of noninvasive markers for the prediction and monitoring of diseases or conditions include preeclampsia, a major cause of mortality and long-term health consequences in both mothers and babies. This invention discloses several new reference markers, each of which can be used alone or with just another reference maker in a normalization process to achieve high diagnostic performance, thus significantly reducing the necessary workload in the normalization effort.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Noninvasive markers in maternal plasma for the prediction of pregnancy-associated complications
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 1 August 2025]
We are inviting expressions of interest (EoI) for commercializing “Noninvasive markers in maternal plasma for the prediction of pregnancy-associated complications” technology. The innovation is developed by Professor POON Liona Chiu-Yee, Professor of Department of Obstetrics and Gynaecology of The Chinese University of Hong Kong (CUHK Reference: 23/MED/1253).
The Technology
Circulating markers in peripheral blood represents a source of noninvasive markers for the prediction and monitoring of diseases or conditions include preeclampsia, a major cause of mortality and long-term health consequences in both mothers and babies. This invention discloses several new reference markers, each of which can be used alone or with just another reference maker in a normalization process to achieve high diagnostic performance, thus significantly reducing the necessary workload in the normalization effort.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.